Suppr超能文献

TLR 激动剂介导的过敏反应抑制与气道固有炎症的增加有关。

TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways.

机构信息

Pulmonary Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, H91-02-01, Birkendorferstr 65, D-88397 Biberach ad Riss, Germany.

出版信息

Pulm Pharmacol Ther. 2011 Apr;24(2):203-14. doi: 10.1016/j.pupt.2010.12.009. Epub 2010 Dec 31.

Abstract

Toll-like receptor (TLR) mediated signaling induces pro-inflammatory responses and can both suppress and exacerbate allergic responses in the airways. The aim of our study was to directly compare the efficacy of different TLR agonists in inhibiting or exacerbating the development of Th2-mediated responses in the airways and investigate if the suppressive effects were associated with increased pro-inflammatory responses. Mice were immunized on day 0, 14 and 21 by intraperitoneal injection of ovalbumin/alum and exposed to ovalbumin aerosol on day 26 and 27. TLR2, TLR3, TLR4, TLR7 and TLR9 agonists (0.001, 0.01, 0.1, or 1 mg/kg) were administered intratracheally 1 h before each allergen exposure. Both the TLR7 and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg. The TLR2 and TLR4 agonists potentiated eosinophilia. All TLR agonists enhanced neutrophil numbers at doses as low as 0.01 mg/kg, in particular TLR2 and TLR4 agonists. TLR7 and TLR9 agonists also significantly reduced IL-4 and IL-5 levels and all TLR agonists, with the exception of TLR7, enhanced the amount IL-1β, IL-6, and TNF-α detected in the whole lung lavage. Only application of TLR9 agonist induced detectable levels of IL-10 in the lung. Suppressive effects of the TLR agonists were not dependent upon IFN-γ and IL-10 or associated with increased numbers of Foxp3(+)CD4(+) Tr cells in the lavage fluid. Airway resistance was reduced significantly only when TLR7 agonist was administered. When applied therapeutically 2 days after allergen exposure, all TLR agonists, except TLR2, similarly reduced airway eosinophilia and IL-4 levels. Taken together our results show that TLR7 agonists had the strongest anti-asthmatic effects with the lowest pro-inflammatory potential, suggesting that activating TLR7 may have the greatest potential to treat allergic disorders in humans.

摘要

Toll-like 受体 (TLR) 介导的信号转导诱导促炎反应,并可抑制和加剧气道中的过敏性反应。我们的研究目的是直接比较不同 TLR 激动剂在抑制或加剧气道中 Th2 介导反应的发展方面的功效,并研究抑制作用是否与促炎反应的增加有关。小鼠在第 0、14 和 21 天通过腹腔注射卵清蛋白/明矾进行免疫接种,并在第 26 和 27 天暴露于卵清蛋白气溶胶中。TLR2、TLR3、TLR4、TLR7 和 TLR9 激动剂(0.001、0.01、0.1 或 1mg/kg)在每次过敏原暴露前 1 小时通过气管内给药。TLR7 和 TLR9 激动剂均剂量依赖性地减少气道嗜酸性粒细胞浸润,而 TLR3 激动剂仅在 1.0mg/kg 剂量下减少气道嗜酸性粒细胞浸润。TLR2 和 TLR4 激动剂增强嗜酸性粒细胞浸润。所有 TLR 激动剂在低至 0.01mg/kg 的剂量下均增强中性粒细胞数量,特别是 TLR2 和 TLR4 激动剂。TLR7 和 TLR9 激动剂还显著降低了 IL-4 和 IL-5 水平,并且所有 TLR 激动剂,除 TLR7 外,增强了在整个肺灌洗液中检测到的 IL-1β、IL-6 和 TNF-α的量。仅 TLR9 激动剂的应用诱导了肺中可检测水平的 IL-10。TLR 激动剂的抑制作用不依赖于 IFN-γ 和 IL-10,也与灌洗液中 Foxp3+CD4+Tr 细胞数量的增加无关。仅当给予 TLR7 激动剂时,气道阻力才显著降低。当在过敏原暴露后 2 天进行治疗性应用时,除 TLR2 外,所有 TLR 激动剂均类似地减少气道嗜酸性粒细胞浸润和 IL-4 水平。总之,我们的结果表明 TLR7 激动剂具有最强的抗哮喘作用,且具有最低的促炎潜力,这表明激活 TLR7 可能具有最大的潜力来治疗人类过敏疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验